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development of mifepristone, a progesterone-receptor antagonist
with an affinity for the receptor greater than progesterone itself
[1]. Early studies of modern medical abortion regimens evaluated
mifepristone alone, primarily at very early gestations. Continued
research demonstrated that adding a prostaglandin analogue
within a few days after mifepristone significantly improved the
efficacy of the treatment [2]. The current FDA-approved regimen
of mifepristone 200 mg with misoprostol treatment 24–48 h later
is effective through 70 days gestation [3]. Ongoing pregnancy as a
reason for treatment failure increases 10-fold from 0.3% at less
than 49 days gestation to approximately 3% at 64–70 days’ gesta-
tion [3–5]. While most women with an ongoing pregnancy opt
for further treatment, such as surgical aspiration, some decide to
continue the pregnancy. Recent UK data show that among 2673
women having a medical abortion from 9 to 10 weeks’ gestation,
90 women had ongoing pregnancies after treatment of whom 9
(10%) opted to continue the pregnancy [6]. Thus, even following
treatment, some women do change their mind.
The non-medical terms ‘‘abortion reversal,” ‘‘medical abortion
reversal” and ‘‘abortion pill reversal” have been used to describe
a purported treatment first published as a case series in the Annals
of Pharmacotherapy in December 2012 [7]. However, medical
abortion cannot be ‘‘reversed,” which would imply putting a preg-
nancy back in the uterus. Conceptually, the goal of progesterone
proponents is mifepristone antagonization with high doses of pro-
gesterone; two small case reports and one large case series have
been published about such treatment [7–9]. Commentaries in the
American Journal of Obstetrics and Gynecology and New England
Journal of Medicine have outlined the numerous scientific and eth-
ical problems with these reports, including lack of control groups,
no confirmation of mifepristone ingestion, failure to establish via-
bility prior to progesterone treatment, and providing experimental
treatment without patient consent or institutional review board
oversight [10,11]. Within the reproductive rights community,
some may even argue that mifepristone antagonization is concep-
tually impossible and potentially harmful to women.
We see a parallel issue in second trimester surgical abortion,
with women requesting osmotic dilator removal in less than 1%
o
n
d
p
c
i
s
l
r
t
m
a
m
n
g
g
b
1
e
r
c
m
u
a
t
c
a
g
t
2
v
2
s
r
p
s
https://doi.org/10.1016/j.contraception.2019.10.016
0010-7824/ 2019 Elsevier Inc. All rights reserved.
⇑ Corresponding author: 4860 Y Street, Suite 2500, Sacramento, CA 95817, USA.
E-mail address: mdcreinin@ucdavis.edu (M.D. Creinin).
Please cite this article as: M. D. Creinin and M. J. Chen, Mifepristone antagoniz
https://doi.org/10.1016/j.contraception.2019.10.016f procedures [12]. Even when providers have reviewed all preg-
ancy options prior to dilator placement, counsel patients that
ilator placement is the start of the procedure, and confirm with
atients that they are absolutely clear in their decision before pro-
eeding, a small minority of women do change their mind. The best
nformation we have about what happens after dilator removal is a
mall case series of 12 women, which demonstrated pregnancy
oss in 50% and complications in 66% of women [12]. Still, when
equested, patient autonomy requires dilator removal.
What should we do for the small fraction of women who change
heir mind after taking mifepristone? Is recommending expectant
anagement or progesterone treatment the better choice? To
nswer this question, we need to understand what happens when
ifepristone is taken without misoprostol, if mifepristone antago-
ization with progesterone works (including the appropriate pro-
esterone route, dose and duration) for all or just for specific
estational age ranges, and what safety concerns are present in
oth scenarios.
. Trying to understand efficacy of mifepristone-only treatment
Two competing systematic reviews, both of which have inher-
nt problems, attempted to establish the continuing pregnancy
ate after mifepristone-only treatment to provide a base rate for
omparison with attempted mifepristone antagonization [13,14].
First, Grossman et al [13] found 11 publications with 17 treat-
ent groups meeting criteria to be included in the review. Contin-
ing pregnancy rates ranged from 0 to 36% when patients were
ssessed generally 1–2 weeks after mifepristone ingestion. Overall,
he review included 1092 women with an intrauterine pregnancy;
ontinuing pregnancies occurred in 193 (18%) after mifepristone
lone. Of note, all but one of the studies included women at 49 days
estation or less. Only six of the included studies clearly defined
he outcome of continuing pregnancy as a viable pregnancy [15–
0]. The other five studies appeared to consider retained non-
iable gestations in the outcome of continuing pregnancies [21–
5].
In 2017, Davenport, Delgado and colleagues [14] published a
econd review as a rebuttal to the review from Grossman et al. This
eview included 12 publications with 16 treatment groups; seven
ublications [15–20,25] had been considered acceptable for inclu-
ion in the analysis by Grossman et al. These authors report aation requires real studies to evaluate safety and efficacy, Contraception,
slightly lower combined continuing pregnancy rate of 13%. While
this review excluded four studies that did not clearly define a con-
tinuing pregnancy as a viable pregnancy [18–21], it did include
three reports of published meeting proceedings that were not
peer-reviewed. Only one published study (by Vervest and Haspels
[26]) in the Davenport et al review was not included in the Gross-
man et al review.
In our own re-evaluation of the peer-reviewed studies included
in both reviews, only seven studies clearly define continuing viable
pregnancy rates after mifepristone alone (Table 1). We excluded
non-peer-reviewed meeting proceedings, three studies that con-
sidered an increasing hCG as evidence of continuing pregnancy
as this could represent viable or non-viable gestations [21,24,25],
and two studies without any definition of continuing pregnancies
in the text [22,23]. The studies in Table 1 include 550 women
who received a wide range of mifepristone dosing, the majority
(n = 468, 88%) of whomwere enrolled in studies with an upper ges-
tational age limit of 49 days or less. Among the four studies using a
single mifepristone dose, only one had a study arm with 200 mg,
the dose used in contemporary clinical practice. The continuing
pregnancy rate was higher with 200 mg (7/30 [23%, 95% confidence
interval 8–38%]) than 600 mg (29/420 [7%, 95% confidence interval
4–9%]), p = .006 (Fisher exact test) [17–20]. However, the number
of women (n = 30) is too little for this statistical comparison to be
considered precise [17].
2. Trying to understand harm
Because we have inadequate data to determine the continuing
pregnancy rate after mifepristone alone, we cannot be certain if
mifepristone antagonization is effective. Some argue that since
progesterone might be effective, is there any harm in offering such
treatment to the rare patient who does change her mind? We do
not know that answer either. Whereas the first two published case
series included only eight women at 10 weeks or less gestation
[7,8], a single large series analyzed 547 women treated in various
ways by 325 different providers with ‘‘high-dose” progesterone,
including progesterone in oil intramuscularly, micronized proges-
terone orally, micronized progesterone capsules administered
vaginally, compounded micronized progesterone vaginal supposi-
tories, progesterone vaginal gel, and progesterone vaginal suppos-
itories [9]. The authors reported continuing pregnancy in 261 (48%)
but did not report any adverse events, side effects, or details of
what happened to the approximately 50% of women for whom
the treatment did not ‘‘work.”
In contrast, mifepristone-only studies for abortion did report
complications, including hemorrhage and transfusion [15,16,26].
Among eight studies that used a single dose of mifepristone
200 mg or 600 mg, no cases of hemorrhage or transfusion occurred,
though these studies were limited to women 49 days gestation or
less [17–20,22–25]. Since medical abortion is available through
70 days [3], what are the risks when mifepristone is used without
misoprostol beyond 49 days? These unanswered questions under-
score that the published case series of progesterone use for
mifepristone antagonization are reports and not clinical trials.
3. Laws based on no science
Unfortunately, in the absence of rigorous evaluations, some
lawmakers are using case reports as medical gospel and passing
laws stipulating mifepristone antagonization as fact. These laws
mandate that women who receive mifepristone be informed that
it may be possible to reverse the effects of mifepristone if they
change their minds. In 2015, Arkansas implemented the first
mandatory abortion reversal counseling. Other states that soon fol-
lowed included Arizona (later repealed in 2016), South Dakota,
Utah, and Idaho. In 2019, Arkansas updated its law to clarify the
information provided to patients, and four states (Oklahoma, Ken-
tucky, Nebraska, and North Dakota) enacted new laws. Kansas also
passed such a law that the governor vetoed. A federal judge
recently blocked the North Dakota law following a lawsuit from
plaintiffs that included the American Medical Association. The
judge’s decision acknowledged that compelling counseling based
on the State’s viewpoint without credible scientific evidence that
the treatment was effective interfered with health care providers’
first-amendment rights. Similarly, when Louisiana was considering
such a law in 2017, a Louisiana Department of Health report in
April 2017 found ‘‘neither sufficient evidence nor a scientific basis
to conclude that the effects of an abortion induced with drugs or
chemicals can be reversed” [27]. Still, states continue to introduce
bills to create similar laws. These laws interfere with our duty to
counsel women about both efficacy and safety, and put providers
in the position of counseling about uproven assurances without
any mention of potential harms. In 2015 and reiterated in August
2017, the American Congress of Obstetricians and Gynecologists
publicly opposed laws mandating reversal information as lacking
scientific standing [28].
4. So, what do we do now?
Abortion providers can either continue to dismiss the concept of
mifepristone antagonization or can work to help patients find
answers. Choosing the latter option is a proactive stance towards
Table 1
Studies reporting the proportion of continuing viable pregnancies after mifepristone alone for medical abortion*
First
author
Year
published
Mifepristone
dose
Duration of
treatment
Number Gestational age
limit (days)
Follow-up (days after
mifepristone)
Complete
abortion
Continuing viable
pregnancy rate
Kovacs [15] 1984 25 mg twice daily 4 days 18 42 14 12 (67%) 2 (11% [0–26%])
50 mg twice daily 4 days 10 42 14 5 (50%) 1 (10% [0–29%])
100 mg twice daily 4 days 8 42 14 5 (63%) 0
Cameron [16]y 1986 150 mg daily 4 days 20 56 14 12 (60%) 5 (25% [11–47%])
Vervest [26] 1985 100–200 mg daily 4 days 35 55 14 25 (71%) 0
200 mg daily 4 days 9 56–70 14 3 (33%) 0
Maria [17]y 1988 200 mg Single dose 30 49 7 19 (63%) 7 (23% [12–41%])
600 mg Single dose 174 49 7 147 (84%) 4 (2% [0.1–5%])
Maria [18]y 1988 600 mg Single dose 149 42 7 131 (88%) 14 (9% [5–14%])
Carol [19] 1989 600 mg Single dose 50 39 NR 40 (80%) 6 (12% [6–24%])
Ylikorkala [20]y 1989 600 mg Single dose 47 43 14 33 (70%) 5 (11% [5–23%])
NR: not reported.
Data presented as n (%) or n (% [95% confidence interval]).
* All studies except Vervest et al [26] included in systematic review by Grossman et al [13]; all studies included in Davenport et al [14].
y Gestational age determination included ultrasound examination.
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providing evidence-based care to patients seeking medical abor-
tion, especially to the very few who may change their mind.
If a woman uses mifepristone and then returns to the same pro-
vider’s office 24 hours later stating she has changed her mind, what
should that provider tell her? Is progesterone itself harmful – likely
not based on widespread use within obstetrics. Does progesterone
actually work for mifepristone antagonization – we don’t know
and can only tell our patient that the existing reports in the litera-
ture are inadequate to answer that question. Is NOT using miso-
prostol harmful, especially if the patient is beyond 49 days
gestation – we also do not know that answer. If one believes that
progesterone treatment cannot antagonize mifepristone, then the
safety of not using misoprostol after starting a mifepristone-miso-
prostol regimen is the real question. Using progesterone for
mifepristone antagonization means not using misoprostol as pre-
scribed. Currently, the rare patient who changes her mind is poten-
tially going to a website to get an experimental treatment rather
than returning to the clinician providing her abortion services.
The answers can only be found in properly conducted clinical trials
that can inform evidence-based decision making and not in poorly
conceived laws based on no science. For FDA approval, new treat-
ments go through safety testing before efficacy testing. It is incum-
bent upon the medical community to conduct proper research on
mifepristone antagonization that evaluates the efficacy and safety
of providing progesterone and not using misoprostol.
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